Evanston, ILNCT07348640Now EnrollingIRB Ready

Steno-occlusive Disease Clinical Trial in Evanston, IL

Access cutting-edge steno-occlusive disease treatment through this phase 3 clinical trial at a research site in Evanston. Study-provided care at no cost to qualified participants.

Sponsored by Guerbet

Quick Self-Assessment

See if you qualify for this Evanston location

Preparing your pre-screening questions…

Expert Care in Evanston

Access steno-occlusive disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related steno-occlusive disease treatment provided free

Apply for This Evanston Location

Check if you qualify for this steno-occlusive disease clinical trial in Evanston, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Evanston

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Evanston site if eligible
  4. 4Begin participation

About This Steno-occlusive Disease Study in Evanston

Compare the diagnostic performance of gadopiclenol against gadoterate meglumine in patients with vascular diseases of supra-aortic, peripheral, or abdominal / renal arteries using MRI

Sponsor: Guerbet

Who Can Participate

Inclusion Criteria

Male or female patients 18 years of age or older willing to participate in the trial and follow all study procedures specified in the protocol.
Patient having read the information in the ICF and having provided his/her consent to participate in writing by dating and signing the ICF prior to any trial related procedure being conducted.
Patient with suspected steno-occlusive disease in supra-aortic (carotid/vertebrobasilar) (a), peripheral (b) or abdominal/renal (c) arteries based on:
clinical signs and symptoms including but not limited to prior stroke, transient ischemic attack (TIA), amaurosis fugax (transient monocular blindness) and/or previous diagnostic tests (CTA, IA-DSA, or ultrasound) or
symptoms of lower-extremity arterial disease (stages II-IV according to the Leriche-Fontaine classification, or 1 to 6 according to Rutherford classification 113 and/or confirmed by previous imaging (Doppler ultrasound, CTA, MRA, IADSA) or
suspected renovascular hypertension based on one or more of the following criteria: i. hypertension refractory to standard therapy ii. acute worsening of pre-existing hypertension iii. abrupt onset of sustained, moderate to severe hypertension at age \<35 years suggestive of fibromuscular dysplasia (FMD) iv. progressive renal insufficiency (creatinine \> 2 mg/dL; no other apparent cause of progressive renal failure based on routine medical history, physical examination, 24-h urine collection and urinary protein excretion) v. abnormal/inconclusive renal doppler ultrasound. vi. other criteria (to be specified)
Are scheduled for or had undergone CTA and/or IA-DSA according to imaging standards to cover the supra-aortic (carotid/vertebrobasilar) and/or peripheral and/or abdominal/renal territory described in this protocol.

Exclusion Criteria

Is a pregnant or lactating female. Exclude the possibility of pregnancy for women of childbearing potential:
by testing on site at the institution (serum βHCG or urine)
by surgical history (e.g., tubal ligation or hysterectomy)
post-menopausal with a minimum 1 year without menses.
Has any known allergy to one or more of the ingredients in the investigational products or has a history of hypersensitivity to other GBCAs.
Has severe renal impairment defined as an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2 calculated using the Modification of Diet in Renal Disease (MDRD) formula.
Has known or suspected acute kidney injury (AKI) based on: a. Increase in serum creatinine by ≥ 0.3 mg/dL (≥ 26.5 μmol/L) within 48 hours or b. Increase in serum creatinine to ≥ 1.5 times baseline, which is known or presumed to have occurred within prior 7 days or c. Urine volume \< 0.5 mL/kg/h for 6 hours
Has received any contrast agent (for MRI, CT, DSA) prior to the first IMP administration or is scheduled to receive any contrast agent between the two MRA or after the second IMP administration.
Has received or is scheduled for therapeutic intervention (e.g., endovascular therapy, vascular surgery, etc.) of any kind for vascular disease in the arterial territory of interest performed between the 2 MRA procedures or between the study MRAs and the CTA/IADSA procedures when applicable.
Has any contraindications to MRI.
Is suffering from severe claustrophobia.
Has received an investigational drug or medical device before admission into this study or scheduled to receive any investigational treatment in the course of the trial.
Was previously included in this trial.
Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post-dose follow-up examinations.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Evanston?

Yes, this clinical trial (NCT07348640) has an active research site in Evanston, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Steno-occlusive Disease Treatment Options in Evanston, IL

If you're searching for steno-occlusive disease treatment options in Evanston, IL, this clinical trial (NCT07348640) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Evanston research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced steno-occlusive disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all steno-occlusive disease clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Evanston, IL

See all ankylosing spondylitis clinical trials recruiting in Evanston — not just this study.

Browse Ankylosing Spondylitis Trials in Evanston →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsAll Conditions →

Ready to Join in Evanston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Evanston, IL